Low density of sigma1 receptors in early Alzheimer's disease

Annals of Nuclear Medicine

Volumn 22, Issue 3, 2008, Pages 151-156

  Mishina, Masahiro ^a,b,c   Ohyama, Masashi ^a,b   Ishii, Kenji ^a   Kitamura, Shin ^b,d   Kimura, Yuichi ^a,e   Oda, Kei Ichi ^a   Kawamura, Kazunori ^a,f   Sasaki, Toru ^a   Kobayashi, Shiro ^c   Katayama, Yasuo ^b   Ishiwata, Kiichi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^d NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^e NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cerebellum; Cortex; Positron emission tomography; Sigma1 receptor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE C 11; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SIGMA 1 OPIATE RECEPTOR; CARBON; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR;

ADULT; AGED; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING KINETICS; BRAIN MAPPING; CEREBELLUM; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYNAMICS; FEMALE; FRONTAL LOBE; HUMAN; IN VIVO STUDY; MALE; NORMAL DISTRIBUTION; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TEMPORAL LOBE; THALAMUS; VOLUNTEER; BRAIN CORTEX; BRAIN LEVEL; CHEMISTRY; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

AGED; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CEREBELLUM; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; THALAMUS; TISSUE DISTRIBUTION;

EID: 42049089609     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0094-z     Document Type: Article

References (44)

1. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006;12:3857-3876.
2. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990;42:355-402.
3. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992;13:85-86.
4. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science (New York) 1988;240:219-221.
5. Su TP. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Critical Rev Neurobiol 1993;7:187-203.
6. Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 2000;7:211-218.
7. 1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev 2001;37:116-132.
8. Hiramatsu M, Hoshino T, Kameyama T, Nabeshima T. Involvement of kappa-opioid and sigma receptors in short-term memory in mice. Eur J Pharmacol 2002;453:91-98.
9. Maurice T, Hiramatsu M, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes: II. Reversion of carbon monoxide-induced amnesia. Brain Res 1994;647:57-64.
10. 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur J Pharmacol 1996;315:1-10.
11. Matsuno K, Matsunaga K, Senda T, Mita S. Increase in extra-cellular acetylcholine level by sigma ligands in rat frontal cortex. J Pharmacol Exp Ther 1993;265:851-859.
12. 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res 1995;690:200-206.
13. 1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996;279:106-113.
14. 1 receptors in the rat brain. Ann Nucl Med 2003;17:73-77.
15. Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigma receptors in the aged monkey brain. Neurobiol Aging 2003;24:745-752.
16. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.
17. 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996;312:267-271.
18. Lobner D, Lipton P. Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett 1990;117:169-174.
19. Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of sigma receptors in Parkinson's disease. Acta Neurol Scand 2005;112:103-107.
20. Jansen KL, Faull RL, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 1993;623:299-302.
21. 1 receptor agonists. Drug News Perspect 2002;15:617-625.
22. 11C]SA4503. Synapse 2001;40:235-237.
23. 1 receptors. Nucl Med Biol 2000;27:255-261.
24. 11C]SA4503. Neuroimage 2007;35:1-8.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
26. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-316.
27. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
28. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48Suppl:9-15.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
30. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
31. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400 W. Ann Nucl Med 1997;11:307-313.
32. 11C]flumazenil PET. Ann Nucl Med 2000;14:193-198.
33. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol 2003;30:833-844.
34. Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol (Berl) 1996;91:174-179.
35. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, et al. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999;13:309-315.
36. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004;3:519-527.
37. Braak H, Braak E, Bohl J, Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J Neurol sci 1989;93:277-287.
38. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997;38:925-928.
39. Larner AJ. The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord 1997;8:203-209.
40. Wegiel J, Wisniewski HM, Dziewiatkowski J, Badmajew E, Tarnawski M, Reisberg B, et al. Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res 1999;818:41-50.
41. Sjöbeck M, Englund E. Alzheimer's disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Disord 2001;12:211-218.
42. Verdile G, Gnjec A, Miklossy J, Fonte J, Veurink G, Bates K, et al. Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology 2004;63:1385-1392.
43. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006;27:1564-1576.
44. 3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int 1998;33:29-34.